Journal of the Neurological Sciences
Volume 288, Issue 1 , Pages 178-181 , 15 January 2010

Central nervous system inflammatory demyelination after rituximab therapy for idiopathic thrombocytopenic purpura

  • Joerg-Patrick Stübgen

      Affiliations

    • Corresponding Author InformationDepartment of Neurology and Neuroscience, Weill Cornell Medical Center/New York Presbyterian Hospital, 525 East 68th Street, New York NY 10065-4897, USA. Tel.: +1 212 746 2334; fax: +1 212 746 8742.

Received 13 March 2009 ,Revised 10 September 2009 ,Accepted 7 October 2009.

References 

  1. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. Depletion on B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435–445
  2. McLaughlin P, Grillo-Lopez A, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825–2833
  3. Kneitz C, Wilhelm M, Tony HP. Effective B cell depletion with rituximab in the treatment of autoimmune diseases. Immunology. 2002;206:519–527
  4. Arkfield DG. The potential utility of B cell-targeted biologic therapy in autoimmune diseases. Rheumatol Int. 2008;28:205–215
  5. Gürcan HM, Keskin DB, Stern JN, Nitzberg MA, Shekani H, Ahmed AR. A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol. 2008;9:10–25
  6. George JN, El-Havake MA, Raskob GE. Chronic idiopathic thrombocytopenic purpura. N Engl J Med. 1995;331:207–211
  7. Stasi R, Pagano A, Stipa E, Amadori S. Rituxiamb chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood. 2001;98:952–957
  8. Garcia-Chavez J, Majluf-Cruz A, Montiel-Cervantes L, Esparza MG-R, Vela-Ojeda J. Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis. Ann Hematol. 2007;86:871–877
  9. Medeot M, Zaja F, Vianelli N, Battista M, Baccarani M, Patriarca F, et al. Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long term follow-up results. Eur J Haematol. 2008;81:165–169
  10. Miller FW, Hess EV, Clauw DJ, Hertzman PA, Pincus T, Silver RM, et al. Approaches for identifying and defining environmentally associated rheumatic disorders. Arthritis Rheumatol. 2000;43:243–249
  11. Stübgen JP. B cell-targeted therapy with rituximab and autoimmune neuromuscular disorders. J Neuroimmunol. 2008;204:1–12
  12. Matsui H, Udaka F, Tamura A, Oda M, Kubori T, Nishinaka K, et al. Multiple sclerosis following splenectomy as treatment for idiopathic thrombocytopenic purpura. Intern Med. 2005;44:747–749
  13. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66:1485–1489
  14. Kerr DA. The lumping and splitting of inflammatory CNS disease. Neurology. 2006;66:1466–1467
  15. Wingerchuk DM, Lucchinetti CF. Comparative immunopathogenesis of acute disseminated encephalomyelitis, neuromyelitis optica, and multiple sclerosis. Curr Opin Neurol. 2007;20:343–350
  16. Petereit H, Rubbert-Roth A. Rituximab levels in cerebrospinal fluid of patients with neurological autoimmune disorders. Mult Scler. 2009;15:189–192
  17. Wekerle H, Lassmann H. The immunology of inflammatory demyelinating disease. In:  Compston A editors. McAlpine's multiple sclerosis. London: Churchill Livingston; 2006;p. 491–555
  18. Cross AH, Stark JL, Lauber J, Ramsbottom MJ, Lyons J-A. Rituximab reduces B cells and T cells in the cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol. 2006;180:63–70
  19. Liossis SN, Sfikakis PP. Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells. Clin Immunol. 2008;127:280–285
  20. Winkler U, Jensen M, Manzke O, Schultz H, Diehl V, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood. 1999;94:2217–2224
  21. Myers KJ, Sprent J, Dougherty JP, Ron Y. Synergy between encephalitogenic T cells and myelin basic protein-specific antibodies in the induction of experimental autoimmune encephalomyelitis. J Neuroimmunol. 1992;41:1–8
  22. Antel J, Bar-Or A. Roles of immunoglobulins and B cells in multiple sclerosis: from pathogenesis to treatment. J Neuroimmunol. 2008;180:3–8
  23. Racke M. The role of B cells in multiple sclerosis: rationale for B-cell-targeted therapies. Curr Opin Neurol. 2008;21:S9–S18Supplement

PII: S0022-510X(09)00905-8

doi: 10.1016/j.jns.2009.10.009

Journal of the Neurological Sciences
Volume 288, Issue 1 , Pages 178-181 , 15 January 2010

Article Tools

* Image Usage & Resolution